

**IN THE CLAIMS:**

D<sup>1</sup>

1. (Amended) A method for producing at least one proteinaceous substance in a eukaryotic cell, said method comprising:

providing a eukaryotic cell having a nucleic acid sequence in the eukaryotic cell's genome, said nucleic acid sequence encoding at least one adenoviral E1 protein, which eukaryotic cell further does not comprise a sequence encoding a structural adenoviral protein in its genome;

providing said eukaryotic cell with a gene encoding a recombinant proteinaceous substance;

culturing said eukaryotic cell in a suitable medium; and

harvesting at least one proteinaceous substance from said eukaryotic cell, said suitable medium, or both said eukaryotic cell and said medium.

D<sup>2</sup>

6. (Amended) A method for producing at least one human recombinant protein in a cell, said method comprising:

providing a human cell, with a gene encoding a human recombinant protein, wherein said human cell has in its genome a sequence encoding at least one adenoviral E1 protein and wherein said human cell further does not produce structural adenoviral proteins;

culturing said human cell in a suitable medium; and

harvesting the human recombinant protein from the human cell, the suitable medium, or both said human cell and said medium.

7. (Thrice amended) The method according to claim 1, wherein said at least one adenoviral E1 protein comprises an E1A protein.

D<sup>3</sup> 11. (Thrice amended) The method according to claim 1, wherein said proteinaceous substance is a protein that undergoes post-translational or peri-translational modification, or a combination thereof.

D<sup>4</sup> 73. (Amended) The method according to claim 6, wherein said human recombinant protein is a protein that undergoes post-translational or peri-translational modification, or a combination thereof.

81. (Amended) The method according to claim 7, wherein said proteinaceous substance comprises a viral protein other than an adenoviral protein.

D<sup>5</sup> 82. (Amended) The method according to claim 77, where said viral protein is selected from the group consisting of: an influenza virus neuramidase or a hemagglutinin; an enterovirus protein or a functional equivalent thereof; a herpes virus protein or a functional equivalent thereof; an orthomyxovirus protein; a retrovirus, a parvovirus or a papovavirus protein; a rotavirus or a coronavirus protein; a togavirus protein, rubella virus protein or an Eastern-, Western-, or Venezuelan equine encephalomyelitis virus protein; a hepatitis causing virus protein, a hepatitis A protein, or a hepatitis B virus protein; and a pestivirus protein, such as hog cholera virus protein or a rhabdovirus protein, such as a rabies virus protein.

83. (Amended) The method according to claim 78, where said viral protein is selected from the group consisting of: an influenza virus neuramidase or a hemagglutinin; an enterovirus protein or a functional equivalent thereof; a herpes virus protein or a functional equivalent thereof; an orthomyxovirus protein; a retrovirus, a parvovirus or a papovavirus protein; a rotavirus or a coronavirus protein; a togavirus protein, rubella virus protein or an Eastern-, Western-, or Venezuelan equine encephalomyelitis virus protein; a hepatitis causing virus protein, a hepatitis A protein, or a hepatitis B virus protein; and a pestivirus protein, such as hog cholera virus protein or a rhabdovirus protein, such as a rabies virus protein.

84. (Amended) The method according to claim 79, where said viral protein is selected from the group consisting of: an influenza virus neuramidase or a hemagglutinin; an enterovirus protein or a functional equivalent thereof; a herpes virus protein or a functional equivalent thereof; an orthomyxovirus protein; a retrovirus, a parvovirus or a papovavirus protein; a rotavirus or a coronavirus protein; a togavirus protein, rubella virus protein or an Eastern-, Western-, or Venezuelan equine encephalomyelitis virus protein; a hepatitis causing virus protein, a hepatitis A protein, or a hepatitis B virus protein; and a pestivirus protein, such as hog cholera virus protein or a rhabdovirus protein, such as a rabies virus protein.

85. (Amended) The method according to claim 80, where said viral protein is selected from the group consisting of: an influenza virus neuramidase or a hemagglutinin; an enterovirus protein or a functional equivalent thereof; a herpes virus protein or a functional equivalent thereof; an orthomyxovirus protein; a retrovirus, a parvovirus or a papovavirus protein; a rotavirus or a coronavirus protein; a togavirus protein, rubella virus protein or an Eastern-, Western-, or Venezuelan equine encephalomyelitis virus protein; a hepatitis causing virus protein, a hepatitis A protein, or a hepatitis B virus protein; and a pestivirus protein, such as hog cholera virus protein or a rhabdovirus protein, such as a rabies virus protein.

86. (Amended) The method according to claim 81, where said viral protein is selected from the group consisting of: an influenza virus neuramidase or a hemagglutinin; an enterovirus protein or a functional equivalent thereof; a herpes virus protein or a functional equivalent thereof; an orthomyxovirus protein; a retrovirus, a parvovirus or a papovavirus protein; a rotavirus or a coronavirus protein; a togavirus protein, rubella virus protein or an Eastern-, Western-, or Venezuelan equine encephalomyelitis virus protein; a hepatitis causing virus protein, a hepatitis A protein, or a hepatitis B virus protein; and a pestivirus protein, such as hog cholera virus protein or a rhabdovirus protein, such as a rabies virus protein.

D<sup>6</sup>  
96. (Amended) The method according to claim 6, wherein said at least one adenoviral E1 protein comprises an E1A protein.

Please add the following new claims:

97. (New) The method according to claim 1, wherein said eukaryotic cell is derived from a primary cell.

98. (New) The method according to claim 1, wherein said eukaryotic cell is derived from a PER.C6 cell.

99. (New) The method according to claim 6, wherein said human cell is derived from a primary cell.

D<sup>7</sup>  
100. (New) The method according to claim 6, wherein said human cell is derived from a PER.C6 cell.

101. (New) The method according to claim 1, wherein said suitable medium is a serum-free medium.

102. (New) The method according to claim 6, wherein said suitable medium is a serum-free medium.

103. (New) The method according to claim 7, wherein said at least one adenoviral E1 protein further comprises an E1B protein.

104. (New) The method according to claim 97, wherein said at least one adenoviral E1 protein further comprises an E1B protein.

D<sup>7</sup> 105. (New) The method according to claim 1, wherein said proteinaceous substance is a protein.